六君子汤加味治疗结肠癌术后化疗患者的临床疗效及对其免疫功能的影响  

Clinical Efficacy of Modified Liujunzi Decoction for Colon Cancer Patients Undergoing Postoperative Chemotherapy and Its Impact on Immune Function

作　　者：史利斌 于倩 葛小栋 王艳 高文侠 于田恬 陆庆革 SHI Li-bin;YU Qian;GE Xiao-dong;WANG Yan;GAO Wen-xia;YU Tian-tian;LU Qing-ge(Department of Ultrasound,Tangshan Hospital of Traditional Chinese Medicine,Tangshan Hebei 063000;Department of Oncology,Tangshan Hospital of Traditional Chinese Medicine,Tangshan Hebei 063000;Department of Proctology,Tangshan Hospital of Traditional Chinese Medicine,Tangshan Hebei 063000;Department of Pharmacy,Tangshan Hospital of Traditional Chinese Medicine,Tangshan Hebei 063000)

机构地区：[1]河北省唐山市中医医院超声科,河北唐山063000 [2]河北省唐山市中医医院肿瘤科,河北唐山063000 [3]河北省唐山市中医医院肛肠科,河北唐山063000 [4]河北省唐山市中医医院药剂科,河北唐山063000

出　　处：《世界中西医结合杂志》2024年第4期827-831,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：河北省中医药管理局2023年度中医药类科学研究课题(2023196)。

摘　　要：目的 观察六君子汤加味治疗结肠癌术后化疗患者的临床疗效及对其机体免疫功能的影响。方法 选取2020年1月—2022年1月期间河北省唐山市中医医院肿瘤科收治的结肠癌术后患者136例,按随机数字表法分为对照组和观察组,每组各68例。对照组予以mFOLFOX6方案化疗,观察组在对照组基础上加用六君子汤加味治疗,以2周为1个周期,12个周期为1个疗程。观察比较两组患者临床疗效、生活质量改善率、不良反应发生率,治疗前后中医证候积分、KPS评分、免疫功能指标。结果 治疗后两组患者KPS评分均较治疗前明显升高,差异有统计学意义(P<0.05);且观察组KPS评分明显高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者中医证候积分均较治疗前明显降低,差异有统计学意义(P<0.05);且观察组中医证候积分明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者Th17和Th17/Treg比值均较治疗前升高,Treg均较治疗前降低,差异有统计学意义(P<0.05);且观察组Th17和Th17/Treg比值均明显高于对照组,Treg明显低于对照组,差异有统计学意义(P<0.05)。治疗后观察组生活质量改善率79.69%(49/64)明显高于对照组53.22%(34/62),差异有统计学意义(P<0.05)。治疗后观察组总有效率95.31%(61/64)明显高于对照组88.71(55/62),差异有统计学意义(P<0.05)。治疗期间,观察组不良反应发生率10.94%(7/64)明显低于对照组24.19%(15/62),差异有统计学意义(P<0.05)。结论 六君子汤加味对结肠癌术后化疗患者的胃肠功能恢复具有积极作用,能有效调节Th17/Treg细胞平衡,减少术后化疗的不良反应及毒副作用。Objective To explore the clinical efficacy of Liujunzi Decoction for colon cancer patients undergoing postoperative chemotherapy and its impact on immune function.Methods A total of 136 colon cancer patients undergoing postoperative chemotherapy in the Department of Oncology,Tangshan Hospital of Traditional Chinese Medicine from January 2020 to January 2022 were selected and divided into a control group and an observation group by random number table,with 68 in each group.The control group received the mFOLFOX6 regimen,while the observation group received modified Liujunzi Decoction on the basis of the control group.One course of treatment included 12 cycles,with two weeks as one cycle.The clinical efficacy,quality of life,adverse reactions,TCM evidence scores,KPS scores,and immune function were compared between the two groups before and after treatment.Results The KPS scores of the two groups increased after treatment(P<0.05),and the observation group had higher scores than the control group(P<0.05).The TCM symptom scores decreased in both groups(P<0.05),and the observation group had lower scores than the control group(P<0.05).The Th17 and Th17/Treg ratio were elevated in both groups after treatment(P<0.05),with the observation group having more elevation or reduction than in the control group(P<0.05).The improvement rate of quality of life in the observation group was 79.69%(49/64),higher than the 53.22%(34/62)in the control group(P<0.05).The total effective rate of the observation group was 95.31%(61/64),higher than the 88.71(55/62)of the control group(P<0.05).During treatment,the incidence of adverse reactions in the observation group was 10.94%(7/64),lower than the 24.19%(15/62)in the control group(P<0.05).Conclusion Modified Liujunzi Decoction positively impacts the recovery of gastrointestinal function in colon cancer patients undergoing postoperative chemotherapy,regulating the balance of Th17/Treg cells,and reducing the adverse reactions and toxic side effects due to postoperative chemotherapy.This mecha

关 键 词：六君子汤加味 结肠癌 化疗 胃肠功能 Th17/Treg细胞平衡 免疫功能 

分 类 号：R735.35[医药卫生—肿瘤]